Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma 2Hematologic Neoplasms 2Subcutaneous panniculitis-like T-cell lymphoma 1Sezary Syndrome 1Recurrence 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Infectious Mononucleosis 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Cytarabine 3Cyclophosphamide 3Vincristine 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Pentetic Acid 2Methotrexate 2Melphalan 2Etoposide 2Doxorubicin 2Carmustine 2tazemetostat 1sargramostim 1pembrolizumab 1fludarabine phosphate 1etoposide phosphate 1ethanolamine oleate 1denileukin diftitox 1Whole-Body Irradiation 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Transplantation 1Thiotepa 1Tacrolimus 1Sulfamethoxazole 1Sodium Chloride 1Saline Solution, Hypertonic 1Saline Solution 1Radiotherapy 1Psychiatric Rehabilitation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Immunoblastic Lymphadenopathy × Brentuximab Vedotin × Clear all
NCT04795869 2023-10-10

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Northwestern University

Phase 2 Withdrawn
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡